BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

557 related articles for article (PubMed ID: 27087012)

  • 1. Diagnostic accuracy of liver imaging reporting and data system (LI-RADS) v2014 for intrahepatic mass-forming cholangiocarcinomas in patients with chronic liver disease on gadoxetic acid-enhanced MRI.
    Joo I; Lee JM; Lee SM; Lee JS; Park JY; Han JK
    J Magn Reson Imaging; 2016 Nov; 44(5):1330-1338. PubMed ID: 27087012
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diagnostic accuracy of prospective application of the Liver Imaging Reporting and Data System (LI-RADS) in gadoxetate-enhanced MRI.
    Kim YY; An C; Kim S; Kim MJ
    Eur Radiol; 2018 May; 28(5):2038-2046. PubMed ID: 29230525
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differentiation of intrahepatic mass-forming cholangiocarcinoma from hepatocellular carcinoma on gadoxetic acid-enhanced liver MR imaging.
    Kim R; Lee JM; Shin CI; Lee ES; Yoon JH; Joo I; Kim SH; Hwang I; Han JK; Choi BI
    Eur Radiol; 2016 Jun; 26(6):1808-17. PubMed ID: 26373763
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Liver imaging reporting and data system v2014 categorization of hepatocellular carcinoma on gadoxetic acid-enhanced MRI: Comparison with multiphasic multidetector computed tomography.
    Joo I; Lee JM; Lee DH; Ahn SJ; Lee ES; Han JK
    J Magn Reson Imaging; 2017 Mar; 45(3):731-740. PubMed ID: 27474328
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hepatocellular carcinoma: Can LI-RADS v2017 with gadoxetic-acid enhancement magnetic resonance and diffusion-weighted imaging improve diagnostic accuracy?
    Zhang T; Huang ZX; Wei Y; Jiang HY; Chen J; Liu XJ; Cao LK; Duan T; He XP; Xia CC; Song B
    World J Gastroenterol; 2019 Feb; 25(5):622-631. PubMed ID: 30774276
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Contrast ultrasound LI-RADS LR-5 identifies hepatocellular carcinoma in cirrhosis in a multicenter restropective study of 1,006 nodules.
    Terzi E; Iavarone M; Pompili M; Veronese L; Cabibbo G; Fraquelli M; Riccardi L; De Bonis L; Sangiovanni A; Leoni S; Zocco MA; Rossi S; Alessi N; Wilson SR; Piscaglia F;
    J Hepatol; 2018 Mar; 68(3):485-492. PubMed ID: 29133247
    [TBL] [Abstract][Full Text] [Related]  

  • 7. LI-RADS Version 2018 Targetoid Appearances on Gadoxetic Acid-Enhanced MRI: Interobserver Agreement and Diagnostic Performance for the Differentiation of HCC and Non-HCC Malignancy.
    Min JH; Lee MW; Park HS; Lee DH; Park HJ; Lee JE; Park SJ; Kim SS; Park SH; Ha SY; Hwang JA; Cha DI; Park B
    AJR Am J Roentgenol; 2022 Sep; 219(3):421-432. PubMed ID: 35319906
    [No Abstract]   [Full Text] [Related]  

  • 8. LI-RADS M (LR-M) criteria and reporting algorithm of v2018: diagnostic values in the assessment of primary liver cancers on gadoxetic acid-enhanced MRI.
    Kim MY; Joo I; Kang HJ; Bae JS; Jeon SK; Lee JM
    Abdom Radiol (NY); 2020 Aug; 45(8):2440-2448. PubMed ID: 32382817
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of gadoxetic acid versus gadopentetate dimeglumine for the detection of hepatocellular carcinoma at 1.5 T using the liver imaging reporting and data system (LI-RADS v.2017).
    Ding Y; Rao SX; Wang WT; Chen CZ; Li RC; Zeng M
    Cancer Imaging; 2018 Dec; 18(1):48. PubMed ID: 30526674
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Liver imaging reporting and data system (LI-RADS) v2018: comparison between computed tomography and gadoxetic acid-enhanced magnetic resonance imaging.
    Nakao S; Tanabe M; Okada M; Furukawa M; Iida E; Miyoshi K; Matsunaga N; Ito K
    Jpn J Radiol; 2019 Sep; 37(9):651-659. PubMed ID: 31321619
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diagnostic accuracy of contrast-enhanced ultrasound for the differential diagnosis of hepatocellular carcinoma: ESCULAP versus CEUS-LI-RADS.
    Schellhaas B; Görtz RS; Pfeifer L; Kielisch C; Neurath MF; Strobel D
    Eur J Gastroenterol Hepatol; 2017 Sep; 29(9):1036-1044. PubMed ID: 28562394
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Imaging features of hepatocellular carcinoma compared to intrahepatic cholangiocarcinoma and combined tumor on MRI using liver imaging and data system (LI-RADS) version 2014.
    Horvat N; Nikolovski I; Long N; Gerst S; Zheng J; Pak LM; Simpson A; Zheng J; Capanu M; Jarnagin WR; Mannelli L; Do RKG
    Abdom Radiol (NY); 2018 Jan; 43(1):169-178. PubMed ID: 28765978
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targetoid hepatic observations on gadoxetic acid-enhanced MRI using LI-RADS version 2018: emphasis on hepatocellular carcinomas assigned to the LR-M category.
    Park HJ; Kim YK; Cha DI; Ko SE; Kim S; Lee ES; Ahn S
    Clin Radiol; 2020 Jun; 75(6):478.e13-478.e23. PubMed ID: 32033745
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined hepatocellular cholangiocarcinoma: LI-RADS v2017 categorisation for differential diagnosis and prognostication on gadoxetic acid-enhanced MR imaging.
    Jeon SK; Joo I; Lee DH; Lee SM; Kang HJ; Lee KB; Lee JM
    Eur Radiol; 2019 Jan; 29(1):373-382. PubMed ID: 29955948
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Curative Resection of Single Primary Hepatic Malignancy: Liver Imaging Reporting and Data System Category LR-M Portends a Worse Prognosis.
    An C; Park S; Chung YE; Kim DY; Kim SS; Kim MJ; Choi JY
    AJR Am J Roentgenol; 2017 Sep; 209(3):576-583. PubMed ID: 28657851
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Liver Imaging Reporting and Data System on CT and gadoxetic acid-enhanced MRI with diffusion-weighted imaging.
    Cha DI; Jang KM; Kim SH; Kang TW; Song KD
    Eur Radiol; 2017 Oct; 27(10):4394-4405. PubMed ID: 28374073
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Added Value of sequentially performed gadoxetic acid-enhanced liver MRI for the diagnosis of small (10-19 mm) or atypical hepatic observations at contrast-enhanced CT: A prospective comparison.
    Yoon JH; Lee JM; Lee YJ; Lee KB; Han JK
    J Magn Reson Imaging; 2019 Feb; 49(2):574-587. PubMed ID: 30102433
    [TBL] [Abstract][Full Text] [Related]  

  • 18. LI-RADS Version 2017 versus Version 2018: Diagnosis of Hepatocellular Carcinoma on Gadoxetate Disodium-enhanced MRI.
    Lee SM; Lee JM; Ahn SJ; Kang HJ; Yang HK; Yoon JH
    Radiology; 2019 Sep; 292(3):655-663. PubMed ID: 31310175
    [TBL] [Abstract][Full Text] [Related]  

  • 19. LI-RADS treatment response categorization on gadoxetic acid-enhanced MRI: diagnostic performance compared to mRECIST and added value of ancillary features.
    Kim SW; Joo I; Kim HC; Ahn SJ; Kang HJ; Jeon SK; Lee JM
    Eur Radiol; 2020 May; 30(5):2861-2870. PubMed ID: 32006170
    [TBL] [Abstract][Full Text] [Related]  

  • 20. LI-RADS v2014 categorization of hepatocellular carcinoma: Intraindividual comparison between gadopentetate dimeglumine-enhanced MRI and gadoxetic acid-enhanced MRI.
    Song JS; Choi EJ; Hwang SB; Hwang HP; Choi H
    Eur Radiol; 2019 Jan; 29(1):401-410. PubMed ID: 29922928
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.